🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the USA / NCT03053141
Recruiting Observational

RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)

NCT03053141 · tracked via the Priya Life Science USA tracker
Sponsor
Boston Scientific Corporation
Phase
Observational
Started
2016-05
Last updated
2026-08-28

Condition(s) studied

Cardiac Arrythmias

Investigational drug(s) / intervention(s)

Rhythmia Mapping System

Rhythmia Mapping System: The Rhythmia Mapping System is a 3D electro-anatomical mapping system.

Study summary

The objective of the RHAPSODY study is to evaluate the performance of new software features in subjects undergoing standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System. Results from this study will be used to guide development and refinement of new software features that may be implemented in future commercial software releases.

Eligibility

Sex
ALL
Min age
18 Years
Max age
Healthy volunteers
No
Inclusion Criteria: 1. Age 18 or above, or above legal age and willing and capable of giving informed consent specific to national law 2. Scheduled for standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System. Exclusion Criteria: 1. Prothrombotic or bleeding tendency due to coagulopathy or blood dyscrasia 2. Inability to tolerate heparin therapy (e.g. heparin induced thrombocytopenia, allergy, etc.) 3. Prosthetic or stenotic valves in the chamber where the intended mapping will occur, or in the path of the catheter access route 4. Active systemic infection or sepsis 5. Hemodynamic instability or shock at baseline precluding ablation in the assessment of the investigator. 6. Presence of intracardiac thrombus, tumor, or other abnormality which precludes catheter introduction 7. Women who are pregnant or lactating 8. Cardiac surgery within the past 90 days 9. Acute myocardial infarction within 3 months 10. Stable/unstable angina or ongoing myocardial ischemia 11. Subjects with an active heart failure decompensation 12. Long QT Syndrome, Brugada Syndrome, or Torsade de Pointes 13. Congenital heart disease with or without corrective surgery that would complicate a mapping procedure 14. Subjects having untreatable allergy to contrast media 15. Vascular pathology or tortuosity precluding standard vascular access techniques 16. Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the patient is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments. Each instance should be brought to the attention of the sponsor to determine eligibility.

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
University of Alabama at Birmingham Birmingham Alabama Completed
St. Lukes Idaho Cardiology Associates Boise Idaho Completed
Lahey Clinic, Inc. Burlington Massachusetts Completed
Cardiovascular Specialists of New England Research Foundation Londonderry New Hampshire Recruiting
Catholic Medical Center Manchester New Hampshire Completed
Valley Hospital Ridgewood New Jersey Completed
Fondazione Centro San Raffaele Milan MI Completed
Centre Hospitalier Princesse Grace Monaco Monaco Completed

More Boston Scientific Corporation trials in the USA

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03053141 on ClinicalTrials.gov ↗ ← All trials in the USA